Hospital
Firsthealth of the Carolinas, INC.
Firsthealth of the Carolinas, INC. was paid $61.58M by Medicaid between Jan 2018 and Dec 2024, across 474 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoFIRSTHEALTH OF THE CAROLINAS, INC.
PINEHURST, NC 28374
PINEHURST, NC 28374
33aNPI1740208081assigned 07/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$61.58M
24GClaims2,306,301
24DCodes billed474
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#5 of 92
Median peer was paid$11.47M
This provider vs. median5.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FOSTER, MICKEY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 525,794 | $11.29M | |
| 2019 | 494,689 | $11.19M | |
| 2020 | 211,739 | $3.96M | |
| 2021 | 285,062 | $8.00M | |
| 2022 | 256,643 | $8.39M | |
| 2023 | 255,747 | $8.55M | |
| 2024incomplete | 276,627 | $10.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 107,631 | 95,063 | $7.94M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.7% | 108,318 | 97,391 | $5.95M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.5% | 6,829 | 6,182 | $4.03M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.5% | 39,486 | 34,808 | $3.39M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.1% | 27,863 | 24,184 | $2.54M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.4% | 13,682 | 12,518 | $2.08M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.4% | 34,597 | 28,995 | $2.07M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 9,182 | 8,252 | $1.74M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 46,544 | 40,501 | $1.64M |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.5% | 30,535 | 24,883 | $1.56M |
| 71046 | Radiologic examination, chest; 2 views | 2.1% | 26,589 | 23,844 | $1.30M |
| 0240U | 1.8% | 6,831 | 6,550 | $1.11M |
462 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 2,792 | $978K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 22,823 | $878K |
| 80053 | Comprehensive metabolic panel | 1.4% | 95,364 | $842K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 15,585 | $820K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 118,290 | $805K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 50,158 | $710K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 9,354 | $603K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 20,935 | $561K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 20,935 | $548K |
| G0378 | Hospital observation service, per hour | <1% | 9,327 | $529K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16,979 | $488K |
| 11045 | <1% | 3,174 | $485K | |
| 71045 | Radiologic examination, chest; single view | <1% | 15,098 | $481K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,232 | $473K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,249 | $470K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,551 | $449K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,418 | $440K |
| 36415 | Collection of venous blood by venipuncture | <1% | 171,155 | $421K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,784 | $415K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 35,206 | $401K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,313 | $395K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 47,017 | $357K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 11,304 | $353K |
| J3490 | Unclassified drugs | <1% | 34,315 | $317K |
| 81025 | <1% | 38,978 | $293K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,913 | $290K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 912 | $256K |
| 87070 | <1% | 21,381 | $253K | |
| 80069 | <1% | 38,684 | $243K | |
| 72100 | <1% | 2,141 | $234K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 864 | $232K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,632 | $225K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,531 | $221K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 868 | $216K |
| 80061 | Lipid panel | <1% | 15,367 | $212K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 8,625 | $211K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 7,096 | $207K |
| 81001 | <1% | 57,157 | $197K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 955 | $194K |
| 84484 | <1% | 28,983 | $192K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,916 | $189K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,104 | $186K |
| 72141 | <1% | 775 | $171K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,346 | $166K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 535 | $160K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 10,328 | $152K |
| 96376 | <1% | 4,166 | $151K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 17,568 | $142K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 494 | $139K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 625 | $135K |
| 85027 | <1% | 23,934 | $131K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,377 | $130K |
| 88142 | <1% | 6,029 | $127K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 9,037 | $125K |
| 86780 | <1% | 8,103 | $124K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 10,329 | $123K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,825 | $122K |
| 73564 | <1% | 2,144 | $116K | |
| 83690 | <1% | 18,446 | $116K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,459 | $114K |
| 73610 | <1% | 1,852 | $113K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 756 | $113K |
| 76801 | <1% | 1,026 | $111K | |
| 73630 | <1% | 1,855 | $111K | |
| 72040 | <1% | 1,217 | $110K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,399 | $107K |
| 70486 | <1% | 653 | $106K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 27,848 | $106K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,848 | $105K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 674 | $95K |
| 83880 | <1% | 4,765 | $89K | |
| 73130 | <1% | 1,517 | $87K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 543 | $86K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 921 | $85K |
| 87481 | <1% | 1,896 | $83K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,089 | $78K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,895 | $76K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 892 | $74K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 218 | $74K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 14,497 | $70K |
| 73030 | <1% | 1,645 | $69K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 937 | $68K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,993 | $67K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,378 | $66K |
| A9270 | Non-covered item or service | <1% | 248,431 | $65K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,114 | $64K |
| 74018 | <1% | 1,400 | $62K | |
| 93041 | <1% | 3,424 | $61K | |
| 36902 | <1% | 408 | $61K | |
| 73110 | <1% | 1,128 | $60K | |
| 81003 | <1% | 25,813 | $60K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,764 | $59K |
| 93971 | <1% | 839 | $57K | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,215 | $57K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 296 | $56K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,998 | $55K |
| 86850 | <1% | 5,044 | $53K | |
| 74019 | <1% | 961 | $53K | |
| 73221 | <1% | 294 | $50K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20,095 | $49K |
| 93970 | <1% | 732 | $49K | |
| 73080 | <1% | 617 | $49K | |
| 93458 | <1% | 74 | $48K | |
| 94664 | <1% | 2,235 | $45K | |
| 77412 | <1% | 1,041 | $45K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 636 | $42K |
| 86803 | <1% | 2,483 | $42K | |
| 87077 | <1% | 4,973 | $41K | |
| 82607 | <1% | 3,126 | $41K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 284 | $41K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 646 | $41K |
| 70491 | <1% | 156 | $41K | |
| 97162 | <1% | 1,250 | $41K | |
| 86762 | <1% | 2,578 | $40K | |
| 77336 | <1% | 1,211 | $40K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 386 | $38K |
| 76870 | <1% | 317 | $38K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,970 | $37K |
| 71250 | <1% | 440 | $37K | |
| 29125 | <1% | 1,074 | $37K | |
| 83735 | <1% | 8,059 | $36K | |
| 72131 | <1% | 149 | $36K | |
| 87186 | <1% | 4,227 | $35K | |
| 73590 | <1% | 596 | $35K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,682 | $34K |
| 84702 | <1% | 3,760 | $34K | |
| 62323 | <1% | 289 | $34K | |
| 73140 | <1% | 707 | $33K | |
| 87340 | <1% | 3,608 | $33K | |
| 83605 | <1% | 5,084 | $33K | |
| 93017 | <1% | 1,040 | $32K | |
| 96367 | <1% | 1,204 | $32K | |
| 72110 | <1% | 263 | $32K | |
| 82948 | <1% | 12,379 | $31K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,157 | $31K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 831 | $31K |
| 73090 | <1% | 545 | $31K | |
| 94760 | <1% | 4,875 | $31K | |
| 76770 | <1% | 287 | $30K | |
| 87040 | <1% | 3,468 | $30K | |
| C1769 | Guide wire | <1% | 1,619 | $30K |
| 87660 | <1% | 1,614 | $29K | |
| 87480 | <1% | 1,614 | $29K | |
| 82105 | <1% | 1,448 | $28K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,220 | $27K |
| 84439 | <1% | 2,865 | $27K | |
| 72070 | <1% | 506 | $26K | |
| 95811 | <1% | 78 | $26K | |
| 86003 | <1% | 174 | $26K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,559 | $26K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,422 | $26K |
| 88307 | <1% | 368 | $25K | |
| 93460 | <1% | 27 | $25K | |
| 97161 | <1% | 1,079 | $25K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,710 | $25K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,778 | $24K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 287 | $24K |
| 77334 | <1% | 306 | $23K | |
| 94761 | <1% | 4,398 | $23K | |
| 82728 | <1% | 2,002 | $22K | |
| 76536 | <1% | 237 | $22K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,141 | $22K |
| 84466 | <1% | 2,104 | $22K | |
| 84112 | <1% | 299 | $21K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 759 | $21K |
| 82677 | <1% | 792 | $20K | |
| 88304 | <1% | 703 | $20K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,737 | $20K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 892 | $19K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,772 | $19K |
| 10060 | <1% | 654 | $18K | |
| 0012A | <1% | 358 | $18K | |
| 12001 | <1% | 525 | $18K | |
| 0002A | <1% | 343 | $18K | |
| 87641 | <1% | 875 | $18K | |
| 36591 | <1% | 2,406 | $17K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,746 | $16K |
| 86901 | <1% | 5,749 | $16K | |
| 86900 | <1% | 5,748 | $16K | |
| 82746 | <1% | 1,331 | $16K | |
| 85379 | <1% | 2,201 | $16K | |
| 87210 | <1% | 3,628 | $15K | |
| 87807 | <1% | 1,224 | $15K | |
| 90715 | <1% | 904 | $15K | |
| 87640 | <1% | 671 | $15K | |
| 12011 | <1% | 449 | $15K | |
| 0001A | <1% | 367 | $15K | |
| 99152 | <1% | 1,064 | $14K | |
| 73502 | <1% | 1,098 | $14K | |
| 86336 | <1% | 791 | $14K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,877 | $14K |
| 97010 | <1% | 1,913 | $14K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,060 | $14K |
| 83540 | <1% | 2,440 | $13K | |
| 87046 | <1% | 529 | $13K | |
| 87081 | <1% | 2,166 | $13K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 74 | $13K |
| 82570 | <1% | 2,475 | $13K | |
| 76642 | <1% | 436 | $12K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 815 | $12K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 4,770 | $12K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,510 | $12K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,333 | $12K |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 314 | $11K |
| 80074 | <1% | 292 | $11K | |
| 82950 | <1% | 1,884 | $11K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 465 | $11K |
| 88342 | <1% | 539 | $11K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,674 | $11K |
| 80305 | <1% | 892 | $10K | |
| 36430 | <1% | 178 | $10K | |
| 29505 | <1% | 299 | $10K | |
| 0011A | <1% | 405 | $10K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 941 | $10K |
| 82077 | <1% | 897 | $10K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,585 | $10K |
| 77280 | <1% | 188 | $10K | |
| 85610 | <1% | 3,847 | $9K | |
| 73560 | <1% | 252 | $9K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,389 | $9K |
| 84153 | <1% | 585 | $9K | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 891 | $9K |
| C1729 | Catheter, drainage | <1% | 642 | $9K |
| 82550 | <1% | 2,024 | $9K | |
| 82803 | <1% | 602 | $9K | |
| 83021 | <1% | 513 | $9K | |
| 73660 | <1% | 136 | $8K | |
| 76942 | <1% | 277 | $8K | |
| 74022 | <1% | 99 | $8K | |
| 93880 | <1% | 143 | $8K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,759 | $8K |
| 85730 | <1% | 2,248 | $8K | |
| 82565 | <1% | 1,268 | $8K | |
| 80047 | <1% | 1,174 | $8K | |
| 77300 | <1% | 245 | $8K | |
| 82043 | <1% | 1,360 | $8K | |
| 73060 | <1% | 187 | $8K | |
| C1776 | Joint device (implantable) | <1% | 12 | $8K |
| 29130 | <1% | 198 | $7K | |
| 85007 | <1% | 2,679 | $7K | |
| Q3014 | Telehealth originating site facility fee | <1% | 587 | $7K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 251 | $7K |
| 87899 | <1% | 648 | $7K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 124 | $7K |
| 81513 | <1% | 1,372 | $7K | |
| 84703 | <1% | 940 | $7K | |
| 83001 | <1% | 382 | $7K | |
| 71101 | <1% | 177 | $6K | |
| 80076 | <1% | 876 | $6K | |
| 86140 | <1% | 1,542 | $6K | |
| 82248 | <1% | 2,289 | $6K | |
| 80164 | <1% | 541 | $6K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,637 | $6K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 400 | $6K |
| 77387 | <1% | 76 | $6K | |
| 84146 | <1% | 313 | $6K | |
| 97597 | <1% | 523 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 237 | $6K |
| 82784 | <1% | 521 | $5K | |
| 88341 | <1% | 109 | $5K | |
| 96417 | <1% | 360 | $5K | |
| 96411 | <1% | 196 | $5K | |
| 87205 | <1% | 1,845 | $5K | |
| 76775 | <1% | 105 | $5K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,603 | $5K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 701 | $5K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 72 | $5K |
| 12002 | <1% | 131 | $5K | |
| 84156 | <1% | 1,227 | $4K | |
| 82951 | <1% | 317 | $4K | |
| 87045 | <1% | 493 | $4K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 807 | $4K |
| 82805 | <1% | 269 | $4K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 35 | $4K |
| 85652 | <1% | 1,858 | $4K | |
| 84100 | <1% | 2,434 | $4K | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 1,051 | $4K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 180 | $4K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,876 | $4K |
| 87147 | <1% | 928 | $4K | |
| 85045 | <1% | 1,273 | $4K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 442 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 72 | $4K |
| 72158 | <1% | 12 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,381 | $4K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 592 | $4K |
| 94762 | <1% | 937 | $4K | |
| 86038 | <1% | 322 | $3K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 609 | $3K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 22 | $3K |
| 73552 | <1% | 203 | $3K | |
| 85014 | <1% | 2,336 | $3K | |
| 87536 | <1% | 141 | $3K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 28 | $3K |
| 82553 | <1% | 452 | $3K | |
| 87510 | <1% | 1,614 | $3K | |
| 97163 | <1% | 70 | $3K | |
| 84403 | <1% | 107 | $3K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 50 | $3K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,057 | $3K |
| 84550 | <1% | 997 | $3K | |
| 77014 | <1% | 39 | $3K | |
| 82040 | <1% | 564 | $3K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 13 | $3K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 16 | $3K |
| 82247 | <1% | 407 | $3K | |
| 83525 | <1% | 182 | $2K | |
| 51798 | <1% | 234 | $2K | |
| 87631 | <1% | 30 | $2K | |
| 83615 | <1% | 635 | $2K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,152 | $2K |
| 83883 | <1% | 211 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 95 | $2K |
| 86923 | <1% | 48 | $2K | |
| 83721 | <1% | 257 | $2K | |
| 84165 | <1% | 451 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 381 | $2K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 33 | $2K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 346 | $2K |
| 36600 | <1% | 307 | $2K | |
| 20610 | <1% | 67 | $2K | |
| 73700 | <1% | 16 | $2K | |
| 87075 | <1% | 308 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 717 | $2K |
| 82150 | <1% | 397 | $2K | |
| 86592 | <1% | 475 | $2K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 505 | $2K |
| 80320 | <1% | 268 | $2K | |
| 29515 | <1% | 49 | $2K | |
| 82947 | <1% | 684 | $2K | |
| 82378 | <1% | 170 | $2K | |
| 59025 | Fetal non-stress test | <1% | 34 | $2K |
| 82375 | <1% | 270 | $2K | |
| 72170 | <1% | 110 | $2K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 240 | $2K |
| 84436 | <1% | 344 | $2K | |
| C1892 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away | <1% | 353 | $2K |
| 72050 | <1% | 13 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 5,207 | $1K |
| 77417 | <1% | 128 | $1K | |
| 90686 | <1% | 173 | $1K | |
| 82272 | <1% | 746 | $1K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 24 | $1K |
| 84481 | <1% | 75 | $1K | |
| 51702 | <1% | 136 | $1K | |
| 84480 | <1% | 121 | $1K | |
| L1930 | Ankle foot orthosis, plastic or other material, prefabricated, includes fitting and adjustment | <1% | 101 | $1K |
| 72082 | <1% | 16 | $1K | |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | <1% | 242 | $1K |
| 82952 | <1% | 293 | $1K | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 24 | $1K |
| 86334 | <1% | 130 | $1K | |
| 83050 | <1% | 269 | $1K | |
| 36000 | <1% | 356 | $1K | |
| 96415 | <1% | 70 | $1K | |
| 77290 | <1% | 14 | $1K | |
| 77001 | <1% | 39 | $1K | |
| 72114 | <1% | 14 | $1K | |
| 93226 | <1% | 16 | $1K | |
| 97035 | <1% | 156 | $998.31 | |
| 93225 | <1% | 16 | $994.32 | |
| 76937 | <1% | 26 | $988.13 | |
| 97165 | <1% | 46 | $974.73 | |
| 85018 | <1% | 717 | $967.05 | |
| 87625 | <1% | 45 | $921.34 | |
| 86376 | <1% | 63 | $906.98 | |
| 11043 | <1% | 12 | $904.75 | |
| 96523 | <1% | 384 | $890.44 | |
| 87522 | Neg quan hep c or qual rna | <1% | 31 | $856.29 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 30 | $850.68 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 200 | $821.86 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 350 | $819.50 |
| 83516 | <1% | 57 | $805.41 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 16,911 | $798.47 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 219 | $752.13 |
| 0003A | <1% | 16 | $745.17 | |
| 73562 | <1% | 16 | $744.51 | |
| 73620 | <1% | 21 | $715.28 | |
| 87449 | <1% | 94 | $714.00 | |
| 96368 | <1% | 52 | $693.06 | |
| 80185 | <1% | 104 | $691.08 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 45 | $678.30 |
| 87324 | <1% | 79 | $658.36 | |
| 88173 | <1% | 16 | $643.81 | |
| L4386 | Walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 44 | $636.22 |
| 84155 | <1% | 493 | $634.65 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 1,295 | $618.61 |
| 97750 | <1% | 278 | $604.49 | |
| 83520 | <1% | 65 | $603.00 | |
| 77333 | <1% | 12 | $586.52 | |
| 70360 | <1% | 12 | $568.72 | |
| 74220 | <1% | 15 | $521.58 | |
| 84132 | <1% | 759 | $515.93 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 80 | $503.04 |
| 86308 | <1% | 81 | $486.08 | |
| J7603 | <1% | 277 | $479.63 | |
| E0110 | Crutches, forearm, includes crutches of various materials, adjustable or fixed, pair, complete with tips and handgrips | <1% | 1,086 | $447.10 |
| 83970 | <1% | 16 | $421.63 | |
| 81002 | <1% | 151 | $420.62 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 63 | $403.44 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 122 | $403.30 |
| 86361 | <1% | 13 | $400.32 | |
| 0031A | <1% | 18 | $375.98 | |
| 10061 | <1% | 15 | $368.91 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 431 | $350.11 |
| 88333 | <1% | 31 | $338.84 | |
| G0008 | Administration of influenza virus vaccine | <1% | 197 | $335.17 |
| 84134 | <1% | 34 | $321.71 | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 67 | $320.65 |
| 86430 | <1% | 66 | $314.19 | |
| 82977 | <1% | 80 | $311.21 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 32 | $302.26 |
| 84450 | <1% | 84 | $295.32 | |
| 82785 | <1% | 15 | $292.68 | |
| 84460 | <1% | 125 | $291.41 | |
| 87184 | <1% | 29 | $290.58 | |
| 84302 | <1% | 264 | $277.65 | |
| 82140 | <1% | 34 | $277.54 | |
| 83002 | <1% | 12 | $276.96 | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 42 | $249.03 |
| 89051 | <1% | 42 | $233.64 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 61 | $231.03 |
| C1780 | Lens, intraocular (new technology) | <1% | 30 | $190.29 |
| 86304 | <1% | 13 | $188.67 | |
| 88172 | <1% | 13 | $187.24 | |
| 77065 | Tomosynthesis, mammo | <1% | 16 | $187.10 |
| 90674 | <1% | 13 | $160.97 | |
| 86706 | <1% | 13 | $160.68 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 13 | $143.38 |
| 36416 | <1% | 177 | $137.05 | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 86 | $132.17 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 787 | $131.01 |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 109 | $119.40 |
| 83550 | <1% | 16 | $118.44 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 247 | $117.83 |
| 43450 | <1% | 15 | $113.88 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 18 | $109.96 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 25 | $98.63 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 15 | $92.12 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 13 | $92.11 |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | <1% | 14 | $79.75 |
| 97116 | <1% | 25 | $59.55 | |
| 51701 | <1% | 341 | $56.43 | |
| C1758 | Catheter, ureteral | <1% | 13 | $52.21 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 25 | $32.28 |
| 36592 | <1% | 13 | $28.37 | |
| 84520 | <1% | 67 | $11.65 | |
| 91300 | <1% | 733 | $1.80 | |
| 91301 | <1% | 763 | $1.68 | |
| 91303 | <1% | 18 | $0.12 | |
| 81511 | 0% | 274 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 243 | $0.00 |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | 0% | 283 | $0.00 |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | 0% | 374 | $0.00 |
| A0427 | Emergency ambulance ride, advanced life support | 0% | 16 | $0.00 |
| 99241 | 0% | 13 | $0.00 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 207 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 789 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 180 | $0.00 |
| A0425 | Ground mileage, per statute mile | 0% | 431 | $0.00 |
| 0598T | 0% | 17 | $0.00 | |
| 99001 | 0% | 59 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFOSTER, MICKEY (CEO)
| Provider | Location | Paid |
|---|---|---|
| FHPG, LLC | Pinehurst, NC | $3.50M |
| Firsthealth of the Carolinas, INC | Pinehurst, NC | $2.94M |
| Firsthealth of the Carolinas, INC | Troy, NC | $2.91M |
| Firsthealth of the Carolinas, INC. | Southern Pines, NC | $2.91M |
| FHPG, LLC | Rockingham, NC | $1.66M |
| Mcpc-9, LLC | Rockingham, NC | $1.58M |
| Mcpc-7, LLC | Hamlet, NC | $1.37M |
| Mcpc-8, LLC | Raeford, NC | $1.31M |
| Mcpc-8, LLC | Hamlet, NC | $1.25M |
| Mcpc-1 LLC | Rockingham, NC | $1.22M |
| FHPG, LLC | Raeford, NC | $1.03M |
| Mcpc-11, LLC | Pinehurst, NC | $994K |
| Mcpc-8, LLC | Asheboro, NC | $893K |
| Mcpc-8, LLC | Sanford, NC | $862K |
| Mcpc-12, LLC | Pinehurst, NC | $859K |
| Mcpc-16, LLC | Raeford, NC | $803K |
| FHPG, LLC | Carthage, NC | $697K |
| Mcpc-2, LLC | Rockingham, NC | $607K |
| Mcpc-8, LLC | Pinehurst, NC | $587K |
| Mcpc-8, LLC | Sanford, NC | $573K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.